New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued a tumor necrosis factor inhibitor (TNFi).
Newer oral medications for rheumatoid arthritis (RA) do work quite well in the "real world," despite some doubts that they would, according to a new study.
Bimekizumab was found to be more cost-effective than most biologics and targeted synthetic disease-modifying antirheumatic drugs in a Swedish healthcare system-based model.